| Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity CA Jacobson, BD Hunter, R Redd, SJ Rodig, PH Chen, K Wright, ... Journal of Clinical Oncology 38 (27), 3095-3106, 2020 | 286 | 2020 |
| Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia I Aldoss, D Yang, A Aribi, H Ali, K Sandhu, MM Al Malki, M Mei, A Salhotra, ... Haematologica 103 (9), e404, 2018 | 248 | 2018 |
| Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation AF Herrera, M Mei, L Low, HT Kim, GK Griffin, JY Song, RW Merryman, ... Journal of Clinical Oncology 35 (1), 24-31, 2017 | 187 | 2017 |
| Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies SM Ansell, MB Maris, AM Lesokhin, RW Chen, IW Flinn, A Sawas, ... Clinical Cancer Research 27 (8), 2190-2199, 2021 | 158 | 2021 |
| Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia I Aldoss, D Yang, R Pillai, JF Sanchez, M Mei, A Aribi, H Ali, K Sandhu, ... American journal of hematology 94 (10), E253, 2019 | 91 | 2019 |
| Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure SM Smith, J Godfrey, KW Ahn, A DiGilio, S Ahmed, V Agrawal, ... Cancer 124 (12), 2541-2551, 2018 | 76 | 2018 |
| Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE MG Mei, HJ Lee, JM Palmer, R Chen, NC Tsai, L Chen, K McBride, ... Blood, The Journal of the American Society of Hematology 139 (25), 3605-3616, 2022 | 72 | 2022 |
| Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: update on clinical trial data and practical considerations for use M Mei, I Aldoss, G Marcucci, V Pullarkat American journal of hematology 94 (3), 358-362, 2019 | 70 | 2019 |
| Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents I Aldoss, S Dadwal, J Zhang, B Tegtmeier, M Mei, S Arslan, MM Al Malki, ... Blood advances 3 (23), 4043-4049, 2019 | 68 | 2019 |
| Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma AF Herrera, J Palmer, P Martin, S Armenian, NC Tsai, N Kennedy, ... Annals of Oncology 29 (3), 724-730, 2018 | 60 | 2018 |
| P38 activation mediates amyloid-β cytotoxicity X Zhu, M Mei, H Lee, Y Wang, J Han, G Perry, MA Smith Neurochemical research 30, 791-796, 2005 | 58 | 2005 |
| MIPSS70+ v2. 0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen H Ali, I Aldoss, D Yang, S Mokhtari, S Khaled, A Aribi, M Afkhami, ... Blood advances 3 (1), 83-95, 2019 | 57 | 2019 |
| Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia I Aldoss, J Zhang, R Pillai, G Shouse, JF Sanchez, M Mei, R Nakamura, ... British journal of haematology 187 (2), e45, 2019 | 56 | 2019 |
| Inhibition of MDR1 overcomes resistance to brentuximab vedotin in Hodgkin lymphoma R Chen, AF Herrera, J Hou, L Chen, J Wu, Y Guo, TW Synold, VN Ngo, ... Clinical Cancer Research 26 (5), 1034-1044, 2020 | 54 | 2020 |
| Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma J Zurko, J Ramdial, M Shadman, S Ahmed, A Szabo, L Iovino, AA Tomas, ... Haematologica 108 (1), 98, 2023 | 53 | 2023 |
| Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers ML Wang, JC Barrientos, RR Furman, M Mei, PM Barr, MY Choi, S de Vos, ... NEJM evidence 1 (1), EVIDoa2100001, 2022 | 50 | 2022 |
| Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma AY Krishnan, M Mei, CL Sun, SH Thomas, JB Teh, T Kang, M Htut, ... Biology of Blood and Marrow Transplantation 19 (2), 260-265, 2013 | 50 | 2013 |
| Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in … I Aldoss, T Stiller, NC Tsai, JY Song, T Cao, NA Bandara, A Salhotra, ... haematologica 103 (10), 1662, 2018 | 49 | 2018 |
| Validity and reliability of value assessment frameworks for new cancer drugs TGK Bentley, JT Cohen, EB Elkin, J Huynh, A Mukherjea, TH Neville, ... Value in Health 20 (2), 200-205, 2017 | 48 | 2017 |
| Outcomes after allogeneic stem cell transplantation in patients with double-hit and double-expressor lymphoma AF Herrera, SJ Rodig, JY Song, Y Kim, GK Griffin, D Yang, L Nikolaenko, ... Biology of Blood and Marrow Transplantation 24 (3), 514-520, 2018 | 43 | 2018 |
